



Professor Peter Horby, Professor Martin Landray  
RECOVERY trial Co-chairs  
Nuffield Department of Population Health  
Oxford

18<sup>th</sup> February 2021

Dear Peter and Martin

**RECOVERY trial DMC report**

The RECOVERY trial DMC reviewed the safety and efficacy data that were available today for the 36,588 patients randomised. For the interventions still in active recruitment, the numbers included in the comparison of each agent with its control were respectively: REGN-COV2 (8,145), aspirin (13,061) and colchicine (10,089), baricitinib (1,146).

For all the treatments under study in RECOVERY, in the light of the available trial data and all relevant external information, we saw no cogent reason to modify the protocol or intake to the study.

The DMC will next review the safety and efficacy data for all treatments on 4<sup>th</sup> March 2021.

Yours sincerely

Professor Peter Sandercock, MA, DM, FRCPE, FESO, FWSO  
Chairman RECOVERY trial DMC  
Emeritus Professor of Medical Neurology, Centre for Clinical Brain Sciences

Cc DMC members, RECOVERY trial office.

CENTRE DIRECTOR Professor S Chandran  
Professor M Dennis Professor A Farrall Professor S Grant Professor J Ironside Professor R Knight Professor S Lawrie  
Professor A McIntosh Professor M Macleod Professor I Marshall Professor D Owens Professor C Ritchie Professor P Sandercock  
Professor R Sellar Professor C Smith Professor C Sudlow Professor L Thomson Professor A Waldman Professor J Wardlaw Professor R Will

The University of Edinburgh, Chancellor's Building, 49 Little France Crescent, Edinburgh, EH16 4SB, UK  
t: +44 (0)131 465 9602 / w: [www.ccbs.ed.ac.uk](http://www.ccbs.ed.ac.uk) / e: [Peter.sandercock@ed.ac.uk](mailto:Peter.sandercock@ed.ac.uk)